TOP TEN perturbations for 1441_s_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1441_s_at
Selected probe(set): 204780_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1441_s_at (204780_s_at) across 6672 perturbations tested by GENEVESTIGATOR:

bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; osteosarcoma, NOS; primary)

Relative Expression (log2-ratio):5.663678
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted).

doxorubicin study 3 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):5.575144
Number of Samples:2 / 2
Experimental doxorubicin study 3
MCF7 cells treated with 2uM doxorubicin for 24 hours. ATC code:
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; osteosarcoma, NOS; primary)

Relative Expression (log2-ratio):5.20922
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondrosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted).

connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; metastatic) / connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic)

Relative Expression (log2-ratio):-5.1780443
Number of Samples:3 / 2
Experimental connective/soft tissue cancer study 1 (PDX; connective and soft tissue, sarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, sarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.
Control connective/soft tissue cancer study 1 (PDX; connective and soft tissue, leiomyosarcoma, NOS; metastatic)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from a metastasis of patients with primary connective and soft tissue, leiomyosarcoma, NOS of the soft tissue (subcutaneously implanted). Metastatic site of patient tumor sample is not reported.

ARC study 1 / untreated MCF-7 cell sample

Relative Expression (log2-ratio):4.797161
Number of Samples:2 / 2
Experimental ARC study 1
MCF7 cells treated with 2uM ARC (4-amino-6-hydrazino-7-beta-d-ribofuranosyl-7H-pyrrolo-(2, 3-d)-pyrimidine-5-carboxamide, NSC 188491) for 24 hours. ATC code:---
Control untreated MCF-7 cell sample
MCF-7 cells untreated.

dengue fever study 10 (DF) / normal naive CD8 T cell sample

Relative Expression (log2-ratio):4.34657
Number of Samples:3 / 5
Experimental dengue fever study 10 (DF)
Activated CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of Thai individuals with Dengue fever (DF) characterized by the WHO 1997. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis.
Control normal naive CD8 T cell sample
Normal naive CD8 T cells derived from peripheral blood mononuclear cells (PBMCs) of healthy Thai individuals. FACS-sorted CD3+, CD8+, CD45RA+, and CCR7+ naive CD8 T subtype cells were used for analysis.

immune cell study 10 (IgG memory B-cell) / immune cell study 10 (naive B-cell)

Relative Expression (log2-ratio):4.306736
Number of Samples:5 / 5
Experimental immune cell study 10 (IgG memory B-cell)
Class switched IgG memory B-cells (IgG+CD27+) isolated from peripheral blood of healthy adult donors (between 25 and 60 years of age). Mononuclear cells were isolated by Ficoll–Paque density centrifugation and CD19+ B-cells were enriched by magnetic cell separation using the MACS system or by negative selection using the EasySep Human B-Cell Enrichment Kit. B-cell suspensions were stained with anti-CD27 APC, anti-IgD PE–Cy7, anti-IgM FITC, and anti-IgG PE or anti-CD21 PE antibodies and sorted with a FACSDiva cell sorter as class switched IgG memory B-cells.
Control immune cell study 10 (naive B-cell)
Naive B-cells (IgM+IgD+CD27-) isolated from peripheral blood of healthy adult donors (between 25 and 60 years of age). Mononuclear cells were isolated by Ficoll–Paque density centrifugation and CD19+ B-cells were enriched by magnetic cell separation using the MACS system or by negative selection using the EasySep Human B-Cell Enrichment Kit. B-cell suspensions were stained with anti-CD27 APC, anti-IgD PE–Cy7, anti-IgM FITC, and anti-IgG PE or anti-CD21 PE antibodies and sorted with a FACSDiva cell sorter as naive B cells.

nutlin-3 (10uM); flagellin (500 ng/ml) study 1 (control vector) / flagellin study 4 (control vector; 500 ng/ml)

Relative Expression (log2-ratio):4.0087576
Number of Samples:6 / 2
Experimental nutlin-3 (10uM); flagellin (500 ng/ml) study 1 (control vector)
Human breast adenocarcinoma cells MCF-7 expressing wild type p53, stably transfected with control empty vector pSUPER, treated with nutlin-3 (10 uM) for 45 hours followed by an additional 3 hours treatment of nutlin-3 (10uM) and flagellin (500 ng/ml). Cells were cultured in RPMI-1640 medium supplemented with 10% heat inactivated FBS and 50 U/ml of penicillin, 50 ug/ml of streptomycin. ATC code:---
Control flagellin study 4 (control vector; 500 ng/ml)
Human breast adenocarcinoma cells MCF-7 expressing wild type p53, stably transfected with control empty vector pSUPER, treated with DMSO 0.1% for 45 hours followed by an additional 3 hours with flagellin (500 ng/ml). Cells were cultured in RPMI-1640 medium supplemented with 10% heat inactivated FBS and 50 U/ml of penicillin, 50 ug/ml of streptomycin.

bone cancer study 1 (PDX; osteosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-3.9617329
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)

Relative Expression (log2-ratio):-3.9151363
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal B-cell; 20uM)
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---